2024
Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection
Reis K, Wolf A, Perumal R, Seepamore B, Guzman K, Ross J, Cheung Y, Amico K, Brust J, Padayatchi N, Friedland G, Naidoo K, Daftary A, Zelnick J, O'Donnell M. Brief Report: Differentiated Service Delivery Framework for People With Multidrug-Resistant Tuberculosis and HIV Coinfection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 34-39. PMID: 38323838, PMCID: PMC11300702, DOI: 10.1097/qai.0000000000003394.Peer-Reviewed Original ResearchMultidrug-resistant tuberculosisDifferentiated service deliveryAntiretroviral therapyElectronic dose monitoring devicesAntiretroviral therapy adherenceMultidrug-resistant tuberculosis treatmentDifferentiated service delivery modelsHIV co-infectionTreatment courseCumulative adherenceTreatment challengesCo-infectionBedaquilineTreatment completionFocus groupsMedication adherenceHIVTreatmentPatterns of medication adherenceAdherenceTuberculosisSubpopulationsHIV/AIDSTreatment stageStage-specific
2023
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial
Ross J, Perumal R, Wolf A, Zulu M, Guzman K, Seepamore B, Reis K, Nyilana H, Hlathi S, Narasimmulu R, Cheung Y, Amico K, Friedland G, Daftary A, Zelnick J, Naidoo K, O’Donnell M. Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa (ADAP-TIV): study protocol for an adaptive randomized controlled trial. Trials 2023, 24: 776. PMID: 38037105, PMCID: PMC10691086, DOI: 10.1186/s13063-023-07520-9.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdherence support interventionsAntiretroviral therapyTreatment regimensAdherence supportPrimary outcomeTreatment supportPsychosocial supportMDR-TB treatment regimensUndetectable HIV viral loadSupport interventionsIntegrase strand transfer inhibitorsAdherence support strategiesComposite clinical outcomeMDR-TB regimensNegative TB culturesCombination antiretroviral therapyComposite primary outcomeHIV treatment outcomesHIV viral loadDrug-resistant tuberculosisStandard of careNew treatment regimensDifferentiated service deliveryStrand transfer inhibitors
2022
Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS
O'Donnell MR, Padayatchi N, Wolf A, Zelnick J, Daftary A, Orrell C, Nimmo C, Baldwin M, Boodhram R, Maharaj B, Amico KR, Naidoo K, Friedland G. Bedaquiline Adherence Measured by Electronic Dose Monitoring Predicts Clinical Outcomes in the Treatment of Patients With Multidrug-Resistant Tuberculosis and HIV/AIDS. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2022, 90: 325-332. PMID: 35195572, PMCID: PMC11077859, DOI: 10.1097/qai.0000000000002940.Peer-Reviewed Original ResearchConceptsMDR-TB treatment outcomesResistance-associated variantsTreatment outcomesAntiretroviral therapyMDR-TBART adherenceMultidrug-resistant tuberculosis treatmentHIV treatment outcomesProspective cohort studyMultidrug-resistant tuberculosisEnd of treatmentTreatment of patientsSuccessful treatment outcomeElectronic dose monitoring devicesHIV/AIDSCohort studyClinical outcomesMultivariable analysisNovel regimensMedication adherenceAdherence thresholdTuberculosis treatmentTreatment completionLow adherenceDose monitoringAdherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis
Bateman M, Wolf A, Chimukangara B, Brust JCM, Lessells R, Amico R, Boodhram R, Singh N, Orrell C, Friedland G, Naidoo K, Padayatchi N, O’Donnell MR. Adherence Measured Using Electronic Dose Monitoring is Associated with Emergent Antiretroviral Resistance and Poor Outcomes in People with Human Immunodeficiency Virus/AIDS and Multidrug-Resistant Tuberculosis. Clinical Infectious Diseases 2022, 75: 1489-1496. PMID: 35352097, PMCID: PMC9617578, DOI: 10.1093/cid/ciac232.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisHuman immunodeficiency virusMDR-TB treatmentART adherenceART resistanceHuman immunodeficiency virus/AIDSEmergent resistanceStandard of careResource-limited settingsTB regimensAntiretroviral resistanceHIV RNAProspective cohortMedication adherenceImmunodeficiency virusPoor outcomeShort followAdherence thresholdCopies/Treatment outcomesDose monitoringResistance mutationsResistance testingPublic hospitalsLinear association
2014
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
Padayatchi N, Abdool Karim SS, Naidoo K, Grobler A, Friedland G. Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial. The International Journal Of Tuberculosis And Lung Disease 2014, 18: 147-154. PMID: 24429305, PMCID: PMC4770013, DOI: 10.5588/ijtld.13.0627.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB patientsSequential treatment armAnti-tuberculosis treatmentAntiretroviral treatmentTreatment armsFirst-line anti-tuberculosis treatmentMultidrug-resistant tuberculosis patientsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionOut-patient clinicDrug susceptibility resultsSAPiT trialTuberculosis patientsClinical outcomesEarly initiationTherapeutic effectVirus infectionMortality ratePatientsTherapeutic outcomesSmall sample sizeTreatmentSusceptibility resultsTuberculosis
2013
Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa
Brust JC, Berman AR, Zalta B, Haramati LB, Ning Y, Heo M, van der Merwe TL, Bamber S, Moll AP, Friedland GH, Shah NS, Gandhi NR. Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa. PLOS ONE 2013, 8: e73975. PMID: 24040132, PMCID: PMC3765317, DOI: 10.1371/journal.pone.0073975.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisBaseline chest radiographSputum smear statusCulture conversionMajority of patientsCD4 countHilar lymphadenopathySmear statusPleural effusionSputum smearChest radiographsAntiretroviral therapy eraCulture conversion rateMedian CD4 countPercent of patientsChest radiograph findingsEnd of treatmentTherapy eraAdvanced immunodeficiencyCavitary diseaseRadiograph findingsHIV statusRadiographic featuresIndependent associationTreatment outcomesAdverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa
Brust JC, Shah NS, van der Merwe TL, Bamber S, Ning Y, Heo M, Moll AP, Loveday M, Lalloo UG, Friedland GH, Gandhi NR. Adverse Events in an Integrated Home-Based Treatment Program for MDR-TB and HIV in KwaZulu-Natal, South Africa. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2013, 62: 436-440. PMID: 23254152, PMCID: PMC3641171, DOI: 10.1097/qai.0b013e31828175ed.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisAdverse eventsAntiretroviral therapyCommon severe adverse eventsMDR-TB/HIVTreatment programConcurrent antiretroviral therapyMDR-TB patientsMDR-TB therapySevere adverse eventsHome-based treatment programHome-based care settingsRural KwaZulu-NatalMost patientsTherapy modificationConcurrent treatmentCare settingsHIVPatientsTherapyKwaZulu-NatalIntegrated HomeTolerabilityHypothyroidismTuberculosis
2012
Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa
Gandhi NR, Weissman D, Moodley P, Ramathal M, Elson I, Kreiswirth BN, Mathema B, Shashkina E, Rothenberg R, Moll AP, Friedland G, Sturm AW, Shah NS. Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. The Journal Of Infectious Diseases 2012, 207: 9-17. PMID: 23166374, PMCID: PMC3523793, DOI: 10.1093/infdis/jis631.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntitubercular AgentsCluster AnalysisCross InfectionDrug Therapy, CombinationEthambutolExtensively Drug-Resistant TuberculosisFemaleGenotypeHIV InfectionsHospitals, RuralHumansIsoniazidMaleMutationMycobacterium tuberculosisPolymorphism, Restriction Fragment LengthPrevalencePyrazinamideRetrospective StudiesRifampinSequence Analysis, DNASouth AfricaConceptsDrug-resistant tuberculosisHuman immunodeficiency virusNosocomial transmissionEpidemiologic linkExtensively Drug-Resistant TuberculosisPoor infection controlSmear-positive tuberculosisMultidrug-resistant tuberculosisHigh HIV prevalencePoint-source outbreakGlobal public health threatPublic health threatResistance-determining regionXDR tuberculosisImmunodeficiency virusHIV prevalenceObservational studyInfection controlRural hospitalsPatientsTuberculosisTugela FerryFragment length polymorphism analysisHealth threatRestriction fragment length polymorphism analysisIntegrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care [Perspectives]
Brust J, Shah N, Scott M, Chaiyachati K, Lygizos M, van der Merwe T, Bamber S, Radebe Z, Loveday M, Moll A, Margot B, Lalloo U, Friedland G, Gandhi N. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care [Perspectives]. The International Journal Of Tuberculosis And Lung Disease 2012, 16: 998-1004. PMID: 22668560, PMCID: PMC3390442, DOI: 10.5588/ijtld.11.0713.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmbulatory CareAnti-HIV AgentsAntitubercular AgentsAttitude of Health PersonnelCaregiversCD4 Lymphocyte CountCoinfectionDelivery of Health Care, IntegratedFeasibility StudiesFemaleHealth Knowledge, Attitudes, PracticeHIV InfectionsHome Care ServicesHumansMaleMedication AdherenceOrganizational ObjectivesPatient Care TeamProgram DevelopmentProgram EvaluationRural Health ServicesSocial SupportSouth AfricaTime FactorsTreatment OutcomeTuberculosis, Multidrug-ResistantViral LoadConceptsMultidrug-resistant tuberculosisHome-based treatmentHIV treatmentAdverse reactionsTreatment outcomesTreatment programHigh HIV prevalent settingsMDR-TB treatmentEscalation of careSevere adverse eventsHIV treatment programsHIV-prevalent settingsCommunity health workersCo-infection ratePatient treatment programTreatment modelPromising treatment modelNew treatment modelRural KwaZulu-NatalHIV-coMonthly culturesAdherence supportAdverse eventsClinical responseHIV outcomes
2009
Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis
Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. The Lancet Infectious Diseases 2009, 9: 153-161. PMID: 19246019, DOI: 10.1016/s1473-3099(09)70041-6.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisTreatment outcomesHIV statusTreatment regimensStrong patient supportProportion of patientsPatient's HIV statusTuberculosis treatment programmesHigher treatment successSuccessful treatment outcomePublic health concernStandardised regimensMDR tuberculosisObserved therapyPatient populationTreatment completionTreatment successInclusion criteriaPatient supportTherapeutic studiesClinical reportsTreatment approachesTreatment durationPatientsSystematic review